genprowebdirectory
News
Insights
A-Lists
Topics
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
Magazine
Resources
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Search
Advertising
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Webinar Sponsorship
eBook Advertising
Email Nurture Campaigns
Ad Terms and Conditions
About GEN
Contact GEN
Create a Free Account
Log In
GEN – Genetic Engineering and Biotechnology News
Mary Ann Liebert, Inc. Publishers
News
News
Circular RNA Plays Key Role in Tissue Repair after a Heart…
Eli Lilly
Lilly Making First Milestone Payment in $1.9B Collaboration with AC Immune
News
Microbiome Hungry for the Right Fiber
Neuroscience
This Receptor Actually Leaves a Sour Taste in One’s Mouth
News
A Denisovan as Pretty as an Epigenetic Picture
Insights
Tech Exclusives
8 Companion Diagnostic Developers Making a Mark
Tech Exclusives
CRISPR-Chip Launched as “Genome Sensor”
Bioprocessing
Controlling Impurities in Cell Culture Media
Insights
10 Takeover Targets to Watch This Fall
Tech Exclusives
Going Viral: The Next Generation of AAV Vectors
A-Lists
Insights
10 Takeover Targets to Watch This Fall
Insights
What the Top 10 Biopharma CEOs Are Making
Insights
Top 10 Companies Leveraging Gene Editing in 2019
Insights
Top 10 Young Companies in the Money, January–July 2019
August 2019 Vol. 39 No. 8
Top 10 Biopharma IPOs of January–June 2019
Topics
All
Bioprocessing
Cancer
Drug Discovery
OMICs
Translational Medicine
Genome Editing
News
Circular RNA Plays Key Role in Tissue Repair after a Heart…
Eli Lilly
Lilly Making First Milestone Payment in $1.9B Collaboration with AC Immune
News
Microbiome Hungry for the Right Fiber
Tech Exclusives
8 Companion Diagnostic Developers Making a Mark
Magazine
Tech Exclusives
Going Viral: The Next Generation of AAV Vectors
Tech Exclusives
Looking Into a Crystal Ball
Tech Exclusives
Liquid Biopsies Intensify Surveillance of ctDNA
Tech Exclusives
Drug–Drug Interaction Studies Look Beyond CYP Activity
Tech Exclusives
3D Bioprinting Makes the Imitation Matrix Real
Resources
All
Posters
Videos
Webinars
eBooks
Podcasts
Events
New Products
Tutorial
Best of the Web
Best Apps
eBooks
Breakthroughs in Immunotherapy
Upcoming Webinars
Pancreatic Cancer Therapeutic Target Visualized Using In Situ Hybridization
Upcoming Webinars
Bring Greater Efficiency to Your Biobank Lab
Upcoming Webinars
Reliable Single Cell Outgrowth: Dark Art or Science?
Subscribe
Create a Free Account
Log In
Get GEN Magazine
Get GEN eNewsletters
Get the GEN Mobile App
Get GEN News from Alexa
Search
Home
Zinc Finger Nucleases
Zinc Finger Nucleases
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Zinc Finger Nucleases
Sangamo Researchers Show Improvements to Zinc Finger Nuclease Technology
Zinc Finger Nucleases
Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition
Zinc Finger Nucleases
Kite, Sangamo Launch Up-to-$3B+ Cancer Cell Therapy Partnership
Zinc Finger Nucleases
Sangamo, Pfizer Partner on Gene Therapy for ALS, FTLD
Zinc Finger Nucleases
Sangamo Genome Editing Trial, Assessing MPS II Candidate, Treats First Patient
Zinc Finger Nucleases
Genetically Engineered Pigs May Fly as Cancer Models
Zinc Finger Nucleases
A Tap of Radiation Enhances Gene Editing of Human Stem Cells
Zinc Finger Nucleases
Gene Editing Technique Boosts Patients’ HIV Resistance
Zinc Finger Nucleases
Genetic Bug Spray? Scientists Alter Mosquitoes’ Sense of Smell
Zinc Finger Nucleases
Sigma Divisions Establish Screening Technology Deals
Zinc Finger Nucleases
Turning on Genes with The Blues
Zinc Finger Nucleases
Synthetic Biology Expands Beyond Bacteria
Zinc Finger Nucleases
Naked ZFNs Point to More Efficient, Safer Gene Therapy
Zinc Finger Nucleases
Shire, Sangamo Ink $13M Up-Front Deal for ZFPs against Hemophilia and...
Zinc Finger Nucleases
Sangamo Stock Nosedives on Decision to Discontinue Lead ZFP Candidate
Load more
Scroll Up
Please wait while you are redirected to the right page...
We use cookies to give you a better experience on genengnews.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Sangamo Therapeutics aims to position itself as a leader in the development of chimeric antigen receptor-modified regulatory T-cell (CAR-Treg) cell therapies for immunological diseases with its planned acquisition of TxCell. [Source: TxCell]](https://www.genengnews.com/wp-content/uploads/2018/08/ENTrIA_recognition_EN_without_entria1024x9291472362223-265x198.png "Sangamo Looks to Expand into CAR-Treg Cell Therapies with TxCell Acquisition")
![Phase II study with diabetic neuropathy candidate SB-509 failed to meet primary and secondary endpoints.[© Argus - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Oct4_2011_4481058_FallingStocksRedBackground_SangamoStocksDrop5916915515-324x160.jpg "Sangamo Stock Nosedives on Decision to Discontinue Lead ZFP Candidate")
